Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Change in Account Payables (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Change in Account Payables for 6 consecutive years, with -$1.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables rose 67.36% year-over-year to -$1.7 million, compared with a TTM value of -$69000.0 through Dec 2025, up 99.28%, and an annual FY2025 reading of -$69000.0, up 99.28% over the prior year.
  • Change in Account Payables was -$1.7 million for Q4 2025 at Xeris Biopharma Holdings, down from $2.0 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $6.9 million in Q1 2023 and bottomed at -$5.2 million in Q4 2024.
  • Average Change in Account Payables over 5 years is -$75700.0, with a median of $188500.0 recorded in 2023.
  • Peak annual rise in Change in Account Payables hit 456.57% in 2024, while the deepest fall reached 2090.0% in 2024.
  • Year by year, Change in Account Payables stood at $4.4 million in 2021, then crashed by 84.15% to $690000.0 in 2022, then plummeted by 151.16% to -$353000.0 in 2023, then plummeted by 1373.94% to -$5.2 million in 2024, then surged by 67.36% to -$1.7 million in 2025.
  • Business Quant data shows Change in Account Payables for XERS at -$1.7 million in Q4 2025, $2.0 million in Q3 2025, and -$4.4 million in Q2 2025.